Details for New Drug Application (NDA): 210064
NDA 210064 describes FOSAPREPITANT DIMEGLUMINE, which is a drug marketed by Accord Hlthcare, Apotex, Aspiro, Baxter Hlthcare Corp, Be Pharms, Caplin, Chartwell Rx, Chia Tai Tianqing, Dr Reddys, Eugia Pharma, Fresenius Kabi Usa, Lupin, MSN, Mylan Labs Ltd, Piramal Critical, Qilu Pharm Hainan, Quagen, and Teva Pharms Usa, and is included in nineteen NDAs. It is available from seventeen suppliers. Additional details are available on the FOSAPREPITANT DIMEGLUMINE profile page.
The generic ingredient in FOSAPREPITANT DIMEGLUMINE is fosaprepitant dimeglumine. There is one drug master file entry for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the fosaprepitant dimeglumine profile page.
The generic ingredient in FOSAPREPITANT DIMEGLUMINE is fosaprepitant dimeglumine. There is one drug master file entry for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the fosaprepitant dimeglumine profile page.
Summary for 210064
| Tradename: | FOSAPREPITANT DIMEGLUMINE |
| Applicant: | Teva Pharms Usa |
| Ingredient: | fosaprepitant dimeglumine |
| Patents: | 0 |
Suppliers and Packaging for NDA: 210064
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| FOSAPREPITANT DIMEGLUMINE | fosaprepitant dimeglumine | POWDER;INTRAVENOUS | 210064 | NDA | Actavis Pharma, Inc. | 0591-4385 | 0591-4385-79 | 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 CARTON (0591-4385-79) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | POWDER;INTRAVENOUS | Strength | EQ 150MG BASE/VIAL | ||||
| Approval Date: | Sep 5, 2019 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
